Bezlotoxumab for prevention of recurrence of Clostridium difficile infection

This evidence review states that Bezlotoxumab is a monoclonal antibody that neutralises C. difficile toxin B, licensed for prevention of infection recurrence in those at high risk. The authors conclude that due to limitations of the evidence and the high cost of treatment, it is difficult to see a place in therapy for this agent.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news